The anti-fibrosis activity of recombinant LAP and tLAP was confirmed based on the following results: (1) Recombinant LAP and tLAP inhibited TGF-β1-induced EMT, inflammation and apoptosis of AML12 cells; (2) Recombinant LAP and tLAP inhibit TGF-β1-induced proliferation and fibrosis of HSC-T6 cells; (3) Recombinant LAP and tLAP have protective effect on CCl4-induced liver injury and liver fibrosis; (4) Recombinant LAP and tLAP inhibit the phosphorylation of Smad2 protein. Here, SMAD2 is linked to Hepatic fibrosis.